Established in
1983, Sun Pharmaceutical Industries Ltd. is an international, integrated,
specialty pharmaceutical company. It manufactures and markets a large basket of
pharmaceutical formulations as branded generics as well as generics in India,
the United States and several other markets across the world. In India, the
company is a leader in niche therapy areas of psychiatry, neurology,
cardiology, gastroenterology, nephrology, orthopedics and ophthalmology. Sun
Pharma has strong skills in product development, process chemistry, and manufacturing
of complex API, as well as dosage forms.
Recently Sun
Pharma and Taro had terminated the merger stating it in the best interest of
the respective companies and shareholders. Sun pharma will continue to hold 66%
in Taro.
In FY 2012-13 Sun
Pharmaceutical acquired
a) U.S.-based DUSA Pharmaceuticals for around $230
million (about Rs.1,250 crore). DUSA Pharmaceuticals, Inc. is a market leader
in photodynamic therapy (PDT), marketing products to dermatologists.
b)URL pharma’s “generic business” from Japanese drug-maker
Takeda for an undisclosed amount.
Invest for long term.
Consolidated financials (Rs in Crore)
Disclaimer: Any purchase/sale of a stock involves a high degree of investment risk. Caution all investors that they may lose some or all of their investment if they decide to purchase any stock listed here.
No comments:
Post a Comment
Comments